Ophthalmologic Examinations in Children With Juvenile Rheumatoid Arthritis

James Cassidy, MD, Jane Kivlin, MD, Carol Lindsley, MD, James Nocton, MD, the Section on Rheumatology, and the Section on Ophthalmology

ABSTRACT
Unlike the joints, ocular involvement with juvenile rheumatoid arthritis is most often asymptomatic; yet, the inflammation can cause serious morbidity with loss of vision. Scheduled slit-lamp examinations by an ophthalmologist at specific intervals can detect ocular disease early, and prompt treatment can prevent vision loss.

INTRODUCTION
Chronic uveitis is an important and sometimes devastating complication of juvenile rheumatoid arthritis (JRA). The intraocular inflammation primarily affects the iris and ciliary body (iritocyclitis), but the choroid may also be involved. Overall, the frequency varies from 2% to 34% in children with JRA. Diagnosis of early involvement is not possible by direct ophthalmoscopy, but slit-lamp examination will reveal the presence or absence of inflammatory cells and increased protein within the anterior chamber of the eye.

Morbidity includes cataracts, glaucoma, band keratopathy, phthisis bulbi, and loss of vision. Visual outcome has improved in the past 20 years; most children have a relatively good prognosis if the disorder is detected and treated early. However, uveitis in children with JRA remains a leading cause of loss of vision and blindness in the United States.

RISK FACTORS FOR CHRONIC UVEITIS
Articular Features
The classification of JRA describes a heterogeneous group of disorders of predominantly peripheral arthritis with onset of disease before 16 years of age. The 3 major onset types defined by clinical manifestations in the first 6 months of the disease are oligoarticular (pauciarticular), polyarticular, and systemic. The onset type is determined by the systemic features of the illness and the number of joints with arthritis at diagnosis. Oligoarticular JRA is defined by involvement of 4 or fewer joints; polyarticular JRA is defined by involvement of >4 joints (usually 10–20); and systemic-onset JRA is defined by quotidian levers during the first 6 weeks of the illness, almost always associated with a characteristic rash. Less than 1% of children with systemic-onset JRA develop chronic uveitis. Most children with uveitis have an oligoarticular onset.
Chronic uveitis may be detected at the time of initial diagnosis of arthritis; however, if not present at onset, it most often presents during the next 4 to 7 years. The period of highest risk is within 4 years of onset of arthritis, although the risk is never entirely absent. Eye involvement precedes involvement of the joints in approximately 5% of cases.

Children with JRA remain at risk of developing uveitis into adulthood. There are reports of uveitis diagnosed initially more than 20 years after onset of arthritis. The activity of the uveal inflammation does not parallel that of the joint disease.

Age
Children at greatest risk of developing uveitis are those with oligoarticular-onset JRA. The peak age of onset of arthritis in oligoarthritis is 1 to 5 years.

Immunogenetic and Serologic Markers
The serologic marker most strongly associated with chronic uveitis is the presence of antinuclear antibodies. Antinuclear antibodies are present in 65% to 90% of children with chronic uveitis and are a major risk factor for its development. They are usually detected in low to moderate titers on HEP-2 cells and are of unknown antigenic specificity. Rheumatoid factor is not usually present in children with JRA, including those with uveitis. Immunogenetic factors may predispose to the development of chronic uveitis. The associated alleles are located predominantly in the major histocompatibility complex (MHC) region on chromosome 6 and involve specificities in the HLA-DR, DP, and DQ regions.

Clinical Characteristics
The onset of ocular inflammation is insidious and asymptomatic in most young children. Because of the lack of symptoms or the cognitive recognition by the child, the exact time of onset of ocular involvement is frequently difficult to determine. This observation emphasizes the requirement for slit-lamp examination by an ophthalmologist at diagnosis of JRA and periodically thereafter.

Signs or symptoms in older children, rare as they are, may include a red eye, decreased vision, unequal pupils, ocular pain, and headaches and should prompt an urgent eye examination. Most cases of uveitis are bilateral (70% to 80%); unilateral disease may progress to bilateral involvement.

Data compiled before widespread therapy with methotrexate and tumor necrosis factor blockers indicated that the prognosis was good in 25% of cases, and 25% of children responded poorly to treatment and/or might require surgery for cataracts or glaucoma. Approximately 50% of patients required prolonged treatment for moderate to severe chronic inflammation; the visual prognosis in these patients remained guarded. Early and aggressive treatment of intraocular inflammation has helped to reduce the morbidity of the ocular disease.

FREQUENCY OF OPHTHALMOLOGIC EXAMINATIONS IN CHILDREN WITH JRA
The suggested frequency of ophthalmologic visits for children with JRA without known uveitis at diagnosis and during follow-up is presented in Table 1. Once uveitis is diagnosed, the pediatric ophthalmologist will determine the frequency of examinations on the basis of response to therapy and complications. Because a substantial number of patients may have the eye disease before or shortly after their arthritis is diagnosed, they should have their initial eye examination within 1 month of the diagnosis of arthritis rather than waiting for the first available appointment.

### TABLE 1
Frequency of Ophthalmologic Examination in Patients With JRA

<table>
<thead>
<tr>
<th>Type</th>
<th>ANA</th>
<th>Age at Onset, y</th>
<th>Duration of Disease, y</th>
<th>Risk Category</th>
<th>Eye Examination Frequency, mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oligoarthritis or polyarthritis</td>
<td>+</td>
<td>≤6</td>
<td>≤4</td>
<td>High</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>≤6</td>
<td>&gt;4</td>
<td>Moderate</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>≤6</td>
<td>&gt;7</td>
<td>Low</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>&gt;6</td>
<td>≤4</td>
<td>Moderate</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>−</td>
<td>≤6</td>
<td>≤4</td>
<td>Moderate</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>−</td>
<td>≤6</td>
<td>&gt;4</td>
<td>Low</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>&gt;6</td>
<td>NA</td>
<td>NA</td>
<td>Low</td>
<td>12</td>
</tr>
<tr>
<td>Systemic disease</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Low</td>
<td>12</td>
</tr>
</tbody>
</table>

ANA indicates antinuclear antibodies; NA, not applicable.
Recommendations for follow-up continue through childhood and adolescence.

SECTION ON OPHTHALMOLOGY, 2004–2005
Edward Buckley, MD, Chairperson
James Ruben, MD
Jane Kivlin, MD
Stephen Glaser, MD
Gregg Lueder, MD
David Granet, MD
Steven Lichtenstein, MD, Immediate Past Chairperson

STAFF
S. Niccole Alexander, MPP

SECTION ON RHEUMATOLOGY, 2004–2005
Michael Henrickson, MD, Chairperson
John Bohnsack, MD
Harry Gewanter, MD
Kathleen Haines, MD
Mary Moore, MD
James Nocton, MD
Carlos Rosé, MD
Charles Spencer, MD, Immediate Past Chairperson
REFERENCES

15. Cimaz RG, Fink CW. The articular prognosis of pauciarticular onset juvenile arthritis is not influenced by the presence of uveitis. *J Rheumatol.* 1996;23:357–359
Ophthalmologic Examinations in Children With Juvenile Rheumatoid Arthritis
James Cassidy, Jane Kivlin, Carol Lindsley and James Nocton

Pediatrics 2006;117;1843
DOI: 10.1542/peds.2006-0421

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/117/5/1843.full.html